Researchers at Lund University and Washington University have identified a blood marker that reflects the amount of Alzheimer’s pathology in the brain. This discovery may play a key role in determining who is most likely to benefit from the new Alzheimer’s drugs.
In brief:
• The blood-based marker (P-tau217) may start to change several years before the onset of Alzheimer’s symptoms. The marker can be measured using a simpler and cheaper analytical method.
• Compared with a highly…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply